Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Apo E structure determines VLDL clearance and atherosclerosis risk in mice
Christopher Knouff, … , Patrick M. Sullivan, Nobuyo Maeda
Christopher Knouff, … , Patrick M. Sullivan, Nobuyo Maeda
Published June 1, 1999
Citation Information: J Clin Invest. 1999;103(11):1579-1586. https://doi.org/10.1172/JCI6172.
View: Text | PDF
Article

Apo E structure determines VLDL clearance and atherosclerosis risk in mice

  • Text
  • PDF
Abstract

We have generated mice expressing the human apo E4 isoform in place of the endogenous murine apo E protein and have compared them with mice expressing the human apo E3 isoform. Plasma lipid and apolipoprotein levels in the mice expressing only the apo E4 isoform (4/4) did not differ significantly from those in mice with the apo E3 isoform (3/3) on chow and were equally elevated in response to increased lipid and cholesterol in their diet. However, on all diets tested, the 4/4 mice had approximately twice the amount of cholesterol, apo E, and apo B-48 in their VLDL as did 3/3 mice. The 4/4 VLDL competed with human LDL for binding to the human LDL receptor slightly better than 3/3 VLDL, but the VLDL clearance rate in 4/4 mice was half that in 3/3 mice. On an atherogenic diet, there was a trend toward greater atherosclerotic plaque size in 4/4 mice compared with 3/3 mice. These data, together with our earlier observations in wild-type and human APOE*2-replacement mice, demonstrate a direct and highly significant correlation between VLDL clearance rate and mean atherosclerotic plaque size. Therefore, differences solely in apo E protein structure are sufficient to cause alterations in VLDL residence time and atherosclerosis risk in mice.

Authors

Christopher Knouff, Myron E. Hinsdale, Hafid Mezdour, Michael K. Altenburg, Masahiko Watanabe, Steven H. Quarfordt, Patrick M. Sullivan, Nobuyo Maeda

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Distribution of plasma lipoproteins, apo E, and apo B-100 in mice fed no...
Distribution of plasma lipoproteins, apo E, and apo B-100 in mice fed normal chow (a–e), HFW (f), and HFC (g). Pooled plasma (100 μL) from 6 age-matched female mice was fractionated by gel filtration chromatography on a Superose 6B column, and 0.5-mL fractions were collected. Fractions containing VLDL, IDL/LDL, and HDL are shown. (a) Total cholesterol was measured in micrograms per fraction. (b) Triglycerides were measured in micrograms per fraction. (c) Apo E (micrograms per fraction) was measured using an ELISA with antibodies specific for human apo E. (d) Apo B-100 was measured using an ELISA with antibodies specific for mouse apo B-100 and is expressed as arbitrary units per fraction. (e) Apo B-100 and apo B-48 of isolated VLDL (80 μL plasma equivalent) or total lipoproteins (25 μL plasma equivalent) from 3/3 and 4/4 mice were viewed by Coomassie blue staining after SDS-PAGE on 3–20% gradient gel. (f) Total cholesterol was measured in micrograms per fraction in at least 5 female mice maintained on an HFW diet for 2 months. (g) Total cholesterol was measured in micrograms per fraction in at least 5 female mice maintained on an HFC diet for 2 months.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts